Litcius/Paper detail

Aspirin after completion of standard adjuvant therapy for colorectal cancer (ASCOLT): an international, multicentre, phase 3, randomised, double-blind, placebo-controlled trial

John Chia, Eva Segelov, Yanhong Deng, Gwo Fuang Ho, Wei Wang, Shuting Han, Atul Sharma, Kefeng Ding, Chen Gong, Mark Jeffery, Chee Kian Tham, Joong Bae Ahn, Louise Nott, Robert Zielinski, Tsu-Yi Chao, Tom van Hagen, Po‐Li Wei, Fiona Day, Shaesta Mehta, Thomas Yau, Jiewen Peng, Theresa Hayes, Yong Li, Mihir Gandhi, Estelle Mei Jye Foo, Nabilah Rahman, Peter M. Rothwell, Raghib Ali, John Simes, Han Chong Toh

2025˜The œLancet. Gastroenterology & hepatology26 citationsDOI

Topics & Concepts

MedicinePlaceboAspirinColorectal cancerAdjuvantInternal medicineCancerOncologySurgeryAlternative medicinePathologyInflammatory mediators and NSAID effectsAntiplatelet Therapy and Cardiovascular DiseasesCancer, Stress, Anesthesia, and Immune Response
Aspirin after completion of standard adjuvant therapy for colorectal cancer (ASCOLT): an international, multicentre, phase 3, randomised, double-blind, placebo-controlled trial | Litcius